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Purpose: To report the preliminary results of oscillatory photodynamic therapy 
(OPDT) for choroidal neovascularization (CNV) and central serous retinopathy (CSR).
Methods: This study included 7 eyes of 6 patients with CSR (2 eyes), idiopathic 
CNV (2 eyes), CNV due to age-related macular degeneration (AMD) (2 eyes), and 
peripapillary CNV secondary to presumed ocular histoplasmosis syndrome (1 eye). 
Intravenous verteporfin (6 mg/m2 body surface area) was infused over 10 minutes 
followed by oscillating laser (wavelength 689 nm) covering slightly beyond the entire 
lesion. An Area Centralis lens was applied and laser was delivered (600 mW/cm2 fluence 
rate and 50 J/cm2 dose). Intravitreal bevacizumab and dexamethasone combination 
therapy was used with OPDT in 4 eyes with CNV; intravitreal dexamethasone and 
triamcinolone acetonide were injected in the other eye with CNV. Clinical examination, 
funduscopy, fluorescein angiography, and optical coherence tomography (OCT) were 
performed at baseline and after treatment.
Results: After mean follow-up of 7.1±5.1 months, visual acuity improved from 
0.87±0.69 logMAR (20/160) to 0.60±0.65 logMAR (20/80) (P = 0.027); central foveal 
thickness decreased from 322±62.1 to 240.7±34.8 microns as measured by OCT 
(P = 0.018). Fluorescein angiography and OCT demonstrated cessation of vascular 
leakage, and resolution of hemorrhage and subretinal fluid in all eyes. No adverse 
events or recurrence were noted.
Conclusion: OPDT was effective in treating CNV lesions and CSR. OPDT may be 
an improvement on standard PDT due to reduced side effects, thermal damage and 
scarring.
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INTRODuCTION
Photodynamic therapy (PDT) has been used 
successfully to treat choroidal neovascularization 
(CNV) secondary to high myopia, age-related 
macular degeneration (AMD), and ocular 
histoplasmosis syndrome (OHS).1-3 It entails 
the intravenous administration of verteporfin 
(Visudyne; Novartis AG, Basel, Switzerland). 
CNV membranes can be treated with a red diode 
laser (689 nm wavelength), administered to the 
CNV, locally activating the verteporfin in the Oscillatory PDT; Peyman et al
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area covered by the laser. The use of a non-
thermal laser in photodynamic therapy (PDT) 
may avoid the risk of permanent destruction 
of the adjacent neurosensory retina as seen 
with conventional photocoagulation therapy.
The retinal pigment epithelium (RPE) and 
choriocapillaris, which together constitute the 
blood-retinal barrier (BRB),4 play a pivotal 
role in the viability and functionality of 
the neurosensory retina.5 RPE changes may 
adversely affect photoreceptor function and 
survival due to disruption of the BRB and 
leakage of fluid into the subretinal space. 
PDT has been shown to induce structural 
changes in the RPE both experimentally6-10 
and clinically11-13. Observed changes in the 
RPE and choriocapillaris depend on light 
intensity, duration of exposure, concentration 
of the photosensitizer, and interval between 
dye administration and laser therapy.8
Mennel et al7 reported that the combination 
of a therapeutic concentration of verteporfin 
and application of non-thermal laser led to a 
morphologically and functionally detectable 
breakdown of the outer BRB function of the RPE 
without damage to RPE cells in vitro. However, 
they stated that increasing the concentration 
of verteporfin (2 mg/ml) resulted in RPE cell 
damage. Several factors were reported to 
influence verteporfin concentration adjacent 
to RPE cells including blood flow, low density 
lipoprotein (LDL) uptake, concentration of 
LDL receptors, size, location and type of CNV, 
and leakage. Persistent RPE cell destruction 
is more severe in younger subjects,11,12 which 
can be due to better perfusion (higher dosage 
of verteporfin at the RPE) as well as clearer 
media (greater activation of verteporfin by the 
laser)14. Animal models have revealed other 
factors which may influence the effectiveness 
of PDT including media opacity,14 intraocular 
pressure, location of treatment within the 
fundus, equivalent fluence (lower energy and 
longer duration), and retreatment as well as 
fundus pigmentation.15
The non-thermal laser used in PDT, like 
thermal lasers, can induce alterations in the 
RPE and breakdown of the BRB, resulting in 
dysfunction of the neurosensory retina. Such 
PDT-induced RPE damage might be reduced 
by individualized treatment that takes into 
account parameters such as media transparency, 
age and gender, and optimized laser energy 
dosage. For example, reduced-fluence PDT has 
been reported to be effective16-18 in terms of 
visual outcomes and safer than standard PDT 
regarding choroidal alterations17,19 as well as RPE 
changes.18 Sacu et al19 reported that reduced-
fluence PDT is more effective than standard 
photodynamic therapy. Additionally, Azab 
et al20 reported a 3-line loss of visual acuity 
in 14% of eyes assigned to reduced-fluence 
PDT as compared to 28% of eyes undergoing 
standard PDT. 
PDT is now infrequently used as monotherapy 
for AMD; it is most often used in combination 
with other treatment modalities.21-25 Reduced 
laser dose and verteporfin concentration 
may be achieved by the simultaneous use of 
intravitreal triamcinolone26,27 or anti- vascular 
endothelial growth factor (VEGF) agents. The 
latter counteract the effect of VEGF,28,29 which is 
known to be increased in PDT-treated area.30,31 
On the other hand, the addition of reduced 
laser dose PDT (12 or 25 J/cm2) to bevacizumab 
therapy has been shown to decrease the number 
of bevacizumab treatments.32
Peyman et al33 used indocyanine green 
(ICG) assisted oscillatory thermotherapy 
(OTT) at individualized subthreshold energy 
levels to elicit primarily a photodynamic effect 
from the laser while reducing the thermal 
effect. This was achieved by applying the 
predetermined subthreshold thermal energy 
level in an oscillatory mode instead of the 
standard stationary mode. OTT prevents 
accumulation of thermal energy in the tissues, 
permitting choriocapillary blood flow and 
convection to cool down heated tissues, thus 
avoiding potential photocoagulative damage. 
This approach allows treating the retina for 
an extended period of time, thereby providing 
more ICG-induced photodynamic effect.
In this pilot study, we studied the primary 
outcomes of oscillatory photodynamic therapy 
(OPDT) using verteporfin. We believe that 
the oscillatory mode allows more precise and 
customized treatment of the lesion. It provides Oscillatory PDT; Peyman et al
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flexibility in treating areas of pathology without 
extending treatment into unaffected tissues; at 
the same time it allows prolonged treatment 
over the neovascular membrane.
METHODS
Consent for off-label treatment was obtained 
after consultation with the Ophthalmic 
Medical Insurance Company (OMIC). This 
prospective study was approved by the Tulane 
University Institutional Review Board. Seven 
eyes of 6 female patients underwent OPDT 
between September 2008 and December 2009. 
Underlying abnormalities included central 
serous retinopathy (CSR, 2 eyes), idiopathic 
CNV (2 eyes), CNV due to AMD (2 eyes), 
and peripapillary CNV from presumed OHS 
(1 eye). Two eyes (cases #3 and 6) had history 
of treatment with anti-VEGF agents and 
one eye (case #4) had frequent recurrences, 
initially treated with thermal laser as well as 
anti-VEGF therapy. Complete ophthalmologic 
examination at baseline, 2 weeks post-treatment, 
and monthly thereafter included assessment of 
visual acuity, fundus examination (non-contact 
90-diopter lens), color fundus photographs, 
and optical coherence tomography (OCT). 
Fluorescein angiography (IMAGEnet System, 
Topcon, Tokyo, Japan) was performed at 
baseline and repeated based on clinical findings. 
Visual acuity was measured with a Snellen chart 
(CP-690, Nidek, Gamagori, Japan) calibrated 
for 20 feet (6 meters) by the line assignment 
method and converted to logMAR notations by 
the Standard Conversion Table for statistical 
analyses.
Intravenous verteporfin (6 mg/m2 body 
surface area) was infused over 10-minutes. 
The Zeiss Visulas 690s laser system (689-nm 
wavelength, Carl Zeiss Meditec Inc., Dublin, 
California, USA) was used to treat the lesion 
for 83 seconds (except case #5 who received 
166 seconds of treatment). In all cases, an 
Area Centralis lens was applied and laser was 
delivered at a standard fluence of 600 mW/cm2 
and dose of 50 mJ/cm2. During the procedure, 
the operator kept the fundus contact lens steady 
while oscillating the laser beam at 2-3 Hertz 
using a spot size equal to half the size of the 
lesion to cover the entire lesion. Precautions 
for exposure to light were reviewed with the 
patient, who was instructed to stay out of 
sunlight and excessive light exposure for 5 
days. The treatment was well tolerated and 
no complications were observed.
Intravitreal injections of bevacizumab 
(1.25 mg) and dexamethasone (1 mg) were 
performed at the same session in 4 eyes with 
CNV. In one eye with recalcitrant idiopathic 
CNV and a possible episode of post-anti-VEGF 
stroke (case #4), intravitreal dexamethasone 
(360 mcg) and triamcinolone acetate (400 mcg) 
were injected. 
RESuLTS
Baseline variables are summarized in Table 1. 
Mean follow-up was 7.1 ± 5.1 months. Mean 
visual acuity improved from 0.87 ± 0.69 logMAR 
(20/160) to 0.58 ± 0.65 logMAR (20/80) after the 
procedure (Wilcoxon signed-rank test, P = 0.027, 
Table 1). Central subfoveal thickness on OCT 
decreased from 322.3 ± 62.1 µm at baseline to 
240.1 ± 34.8 µm after the procedure (Wilcoxon 
signed-rank test, P = 0.018). Volumetric 
measurements in case #5 showed that pigment 
epithelial detachment/scar and subretinal fluid 
were significantly reduced.
There were no instances of infusion-related 
back pain, photosensitivity reactions, or injection 
site adverse events. Two representative cases 
are described below in detail. 
Case 1
The first patient was a 70-year-old lady with 
longstanding CSR in her left eye and no 
history of treatment. Pigment mottling was 
evident on color fundus photography with 
angiographic activity in the inferotemporal 
macula. Subretinal fluid was present on OCT 
with serous neurosensory detachment in the 
macula (Figures 1a-c). At baseline, visual 
acuity was 20/100 and OCT demonstrated 
central subfoveal thickness of 310 µm with loss 
of photoreceptor inner and outer segments. 
She was treated with OPDT and verteporfin Oscillatory PDT; Peyman et al
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(2400-µm spot size, 600 mW/cm2 fluence rate, 
and 50 mJ/cm2 dose for 83 seconds). After 
treatment, the serous detachment resolved 
and the patient remained clinically stable 
as determined by angiography and OCT 
(Figures 1d-e). Visual acuity improved to 
20/40 without metamorphopsia and central 
subfoveal thickness was decreased to 180 µm. 
Due to disruption of the photoreceptor layer 
and RPE attenuation due to longstanding 
neurosensory detachment, recovery of visual 
acuity was incomplete. The patient remained 
stable up to 11 months. 
Case 3
This 34-year-old lady had mild myopia and 
reduced visual acuity in her left eye. She 
presented with a grayish subretinal lesion 
in the nasal fovea associated with subretinal 
hemorrhage, exudation and retinal thickening 
extending into the center of the fovea. Leakage 
and retinal thickening in the nasal fovea were 
confirmed with fluorescein angiography and 
OCT (Figures 2a-c). She was diagnosed with 
idiopathic choroidal neovascular membrane, 
which did not respond to an injection of 
No.
Age
(yr)
History of 
Treatment
R/L Diagnosis
F/u 
(mo)
VA (LogMAR) Spot 
Size
(µm)
OCT 
measurement 
(µm)
Adjunctive
treatments
Duration
(s)
Details
Pre Post Pre Post
1 70 L CSR 11 20/100 
(0.7)
20/40
(0.3)
2400 310 180 none 83 Hypercholesterolemia, 
ocular   hypertension 
(on Alphagan)
2 62 L CSR 3.5 20/50
(0.4)
20/30
(0.2)
3000 343 207 Intravitreal
Avastin (1.25 
mg)
83
3 34 Avastin (x1) L Idiopathic
CNV
5 20/40
(0.3)
20/25
(0.1)
800 263 250 Intravitreal
Avastin (1.25 
mg)/
Decadron (1 
mg)
83
4 52 Argon;
Avastin (x3);
Lucentis (x2);
Conventional 
PDT
R Idiopathic
recurrent 
CNV
17 20/200
(1)
20/40
(0.3)
2000 450 253 Intravitreal
Decadron (360 
mcg)/
Kenalog (400 
mcg)
83 HTN; hypothyroid;
possible post-anti-
VEGF stroke
5 70 L CNV
from AMD
6 20/200
(1)
20/100
(0.7)
800 305
*2.31 
mm3
272
*0.78 
mm3
Intravitreal
Avastin (1.25 
mg)/
Decadron (500 
mcg)
83 HTN; hyperlipidemia; 
heavy smoker; 
coronary artery 
disease
6 71 Avastin (x3) R Macular 
CNV
from AMD
3 1/200
(2.3)
2/200
(2)
1200 311 276 Intravitreal
Avastin (1.25 
mg)/
Decadron (1 
mg)
83 HTN; hypothyroid; 
glaucoma (Travatan)
7 71 L Peripapillary 
CNV from 
POHS
4 20/50
(0.4)
20/60
(0.5)
900 274 243 Intravitreal
Avastin (1.25 
mg)/
Decadron (1 
mg)
83 5 years ago gamma 
knife for trigeminal 
neuralgia on the left 
side
Table 1. Pre- and post-treatment data for six female patients (7 eyes) undergoing oscillatory photodynamic therapy 
(OPDT) with verteporfin
yr, year; R, right; L, left; F/U, follow-up; mo, month; VA, visual acuity; Pre, pre-treatment; Post, post-treatment; OCT, optical coherence 
tomography; CSR, central serous retinopathy; CNV, choroidal neovascularization; PDT, photodynamic therapy; HTN: hypertension; 
AMD, age-related macular degeneration; POHS, presumed ocular histoplasmosis syndrome. 
*Volumetric measurement shows significant reduction in overall volume (including pigment epithelial detachment and subretinal 
fluid) after treatment.Oscillatory PDT; Peyman et al
170 JOURNAL OF OPHTHALMIC AND VISION RESEARCH 2011; Vol. 6, No. 3
Figure 1. A 70-year-old female patient with chronic central serous retinopathy in the left eye (case #1). Pre-treatment: 
Color fundus photograph shows serous neurosensory detachment of the macula with pigment mottling (a). Fluorescein 
angiography shows multifocal areas of increasing hyperfluorescence in the inferior temporal macula consistent with 
leakage (b). OCT confirms subretinal fluid (central subfoveal thickness 310 µm) with loss of photoreceptor cells (c). Post-
treatment: Color fundus photograph (d), fluorescein angiography (e) and OCT (central subfoveal thickness 180 µm) 
(f) all demonstrate resolution of the serous detachment with a similar amount of pigmentary changes in the macula.Oscillatory PDT; Peyman et al
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Figure 2. A 34-year-old female patient with idiopathic choroidal neovascular membrane (CNVM) in the left eye 
(case  #3). Pre-treatment: Color fundus photograph shows deep subretinal hemorrhage associated with retinal 
thickening and lipid exudation in the nasal macula (a). Fluorescein angiography demonstrates multiple leakage sites 
from the CNVM in the nasal macula (b). OCT confirms retinal thickening in the nasal fovea with a hyper-reflective 
subretinal lesion (central subfoveal thickness 263 µm) (c). Post-treatment: Color fundus photograph (d), fluorescein 
angiography (e), and OCT (central subfoveal thickness 250 µm) (f) all show a consolidated subretinal scar without 
persistent leakage or associated retinal thickening, consistent with involution of CNVM. OCT from the adjacent area 
shows slightly disrupted but mostly preserved photoreceptor layer despite OPDT. The scar appears hyperfluorescent 
and there is a ring of hypofluorescence corresponding to blockage from pigment migration. There are two small areas 
of hyperfluorescence nasal to the fovea consistent with window defects.Oscillatory PDT; Peyman et al
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intravitreal bevacizumab. At baseline, visual 
acuity was 20/40 and central subfoveal thickness 
was 263 µm. She was treated with OPDT and 
verteporfin (800-µm spot size for 83 seconds) 
as well as adjunctive intravitreal bevacizumab/ 
dexamethasone. After treatment the patient had 
a consolidated subretinal scar in the nasal fovea 
without persistent leakage on angiography, 
or fluid on OCT which demonstrated central 
subfoveal thickness of 250 µm (Figures 2d-f). 
The treated perifoveal retina showed relatively 
preserved photoreceptor structure on OCT. 
Visual acuity improved to 20/25 without 
metamorphopsia. There was no recurrence up 
to 5 months after treatment.
DISCuSSION
Herein, we report the preliminary outcomes of 
OPDT with a strong photosensitizer, verteporfin 
in 7 eyes with CNV or CSR. This report describes 
a novel application of PDT in an oscillatory 
fashion. The current realistic goal of PDT is 
to retard progression of CNV due to AMD 
and other causes, and possibly restore normal 
vision without causing significant scarring. We 
believe that oscillatory PDT reduces the risk 
of retinal pigment epithelial damage since it 
decreases total fluence which itself depends 
on the speed of the oscillation. By using small 
spot size and moving it over the treatment area, 
one can avoid treatment of healthy retina; this 
advantage is especially marked for irregularly 
shaped lesions. 
The primary outcome measure in PDT 
studies is to assess the proportion of eyes that 
avoid moderate visual loss (loss of fewer than 
3 lines or 15 letters).1 Our clinical outcomes 
with mean follow-up of 7 months showed 
that OPDT with verteporfin was successful 
in improving central vision in all eyes except 
one (case #7), in which the 1-line reduction in 
visual acuity could be attributed to progression 
of the disease or increased cataract. The 
remaining cases showed 37.4% improvement 
in visual acuity equivalent to 3 Snellen lines. 
Additionally, post-treatment findings on 
funduscopy, fluorescein angiography, and 
OCT were suggestive of cessation of vascular 
leakage as well as resolution of hemorrhage 
and subretinal fluid in all cases.
Cardinal features of PDT include the 
coexistence of a sensitizer, light, and oxygen. 
The main mechanism of action of PDT is vascular 
occlusion due to damage to endothelial cells 
and subsequent thrombosis of both neovascular 
and normal choriocapillaris.34,35 The response to 
PDT appears to be caused by a combination of 
direct cytotoxicity to vascular endothelial cells, 
subsequent platelet adhesion and degranulation, 
thrombosis, and vasoconstriction, leading to 
blood flow stasis and vaso-occlusion of the 
choriocapillaris. PDT exerts its cytotoxic effect 
by generation of reactive oxygen species, which 
can induce cell death either by apoptosis or 
necrosis; it can even initiate a remodeling 
response.34,35 This vascular reaction has been 
associated with variable damage to the RPE 
and photoreceptors.6-13
Application of the laser in an oscillatory 
fashion can potentially reduce damage to the 
RPE by reducing overall fluence. A laser beam 
with spot size of approximately one half the 
size of the lesion is moved 2-3 times per second 
in continuous fashion over the entire treatment 
area. The term fluence takes into account the 
energy level used for treatment, with laser spot 
and application time for coverage of the entire 
lesion in stationary fashion. It can be estimated 
that if the laser is in any particular spot for 
about 0.5 second during the 2 Hz oscillatory 
mode, total fluence is approximately reduced 
to half the standard method of application. 
The power setting in our series (600 mW/cm2) 
and application time (83 seconds) were equal 
to a standard protocol. No visible whitening 
or subsequent fibrotic reaction was observed 
from OPDT application. We used bevacizumab 
and dexamethasone in combination with OPDT 
for most of our patients.36 Dexamethasone, and 
in one case, triamcinolone acetate, was added 
to control the inflammatory response to laser 
therapy.29 
Peyman et al15 showed that PDT retreatment 
resulted in progressive thinning of the 
neurosensory retina with loss of photoreceptor 
outer segments and nuclei in the rabbit eye. In the 
current study, no patient required retreatment Oscillatory PDT; Peyman et al
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and no significant loss of photoreceptors was 
observed on OCT. This outcome can be due to 
both the oscillatory mode of PDT application 
and triple therapy. Triple therapy significantly 
reduces the number of treatments.22,37-39 It is 
noteworthy that three treated eyes had been 
recalcitrant to previous anti-VEGF therapy 
(Table 1). 
OPDT is an improved mode of applying 
standard treatment allowing greater activation 
of the photosensitizer and less cytotoxic damage 
to the neuroretina due to reduced fluence. This 
is evidenced by the lack of a “burn spot” or 
loss of photoreceptors on post-treatment color 
images, fluorescein angiography, and OCT. It is 
impossible to completely prevent the recurrence 
of CNV in choroidal disease, especially in AMD. 
Thus, there will likely be subjects who require 
retreatments. Standard PDT retreatments can 
cause scarring and fibrosis,40,41 but we expect 
this to be less likely with oscillatory PDT.
PDT with verteporfin has been effective for 
chronic CSR by improving visual acuity and 
reducing subretinal fluid.42-47 PDT treatment 
for CSR causes short-term choriocapillaris 
hypoperfusion and long-term choroidal vascular 
remodeling, leading to reduction in choroidal 
congestion, vascular hyperpermeability, 
and extravascular leakage.42,48,49 However, 
complications such as secondary CNV, persistent 
choriocapillaris hypoperfusion, and pigmentary 
RPE changes in the treated zone have been 
reported.42,46,50,51 Modified PDT protocols in 
terms of verteporfin dosage, fluence rate, time 
course of delivery, or a combination thereof have 
been suggested.52 Reibaldi et al53 showed that 
low-fluence PDT is effective in long-standing 
chronic CSR with foveal and gravitational 
atrophy of the retina and reported functional 
improvement without significant retinal or 
choroidal damage. In a comparative study17 
they reported that both standard- and low-
fluence PDT resulted in complete subretinal 
fluid reabsorption and visual improvement. 
PDT-related choroidal hypoperfusion could 
be reduced by low-fluence PDT.
OPDT offers the choice of early treatment for 
CSR; this may prevent atrophy of photoreceptors 
caused by long-standing subretinal fluid 
leading to compromised retinal function. Two 
subjects in this study had chronic CSR (cases 
#1 and #2). They both showed significant 
improvement in visual acuity as well as 
resolution of subretinal fluid with a single 
OPDT treatment, without PDT-related side 
effects and need for retreatment. The chronic 
nature of subretinal fluid was the reason for 
incomplete recovery of visual acuity. There was 
no significant disruption of the neuroretina on 
post-treatment OCT.
This pilot study reports on the outcomes 
of therapy with a novel method of oscillatory 
PDT with verteporfin. Standard PDT has fallen 
out of favor due to the success of anti-VEGF 
therapy. However, drawbacks to repeated 
intraocular injections include the risk of 
endophthalmitis and retinal detachment, as well 
as an overwhelming cost to healthcare systems. 
OPDT may be applied for all CNV lesions and 
reduce the need for repeat injections. Even 
though there are reports of CSR responding 
to anti-VEGF therapy, there are recalcitrant 
cases that will still require laser treatment.54,55 
OPDT appears to be an improved method of 
administering PDT and is effective in treating 
CNV lesions and CSR. It may be superior 
to standard PDT because of reduced total 
fluence and enhanced photodynamic effect. 
Furthermore, it allows the operator to customize 
treatment over the lesion, potentially spending 
more time over more aggressive components of 
the choroidal neovascular membrane. Smaller 
spot size also reduces inadvertent treatment of 
normal retina which may occur with irregular 
shaped lesions.
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